1. Home
  2. EEX vs DVAX Comparison

EEX vs DVAX Comparison

Compare EEX & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EEX
  • DVAX
  • Stock Information
  • Founded
  • EEX 2013
  • DVAX 1996
  • Country
  • EEX United States
  • DVAX United States
  • Employees
  • EEX N/A
  • DVAX N/A
  • Industry
  • EEX Advertising
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EEX Consumer Discretionary
  • DVAX Health Care
  • Exchange
  • EEX Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • EEX 1.0B
  • DVAX 1.2B
  • IPO Year
  • EEX 2017
  • DVAX 2004
  • Fundamental
  • Price
  • EEX $4.91
  • DVAX $10.15
  • Analyst Decision
  • EEX Strong Buy
  • DVAX Buy
  • Analyst Count
  • EEX 2
  • DVAX 4
  • Target Price
  • EEX $7.95
  • DVAX $26.50
  • AVG Volume (30 Days)
  • EEX 51.4K
  • DVAX 1.7M
  • Earning Date
  • EEX 10-29-2025
  • DVAX 11-06-2025
  • Dividend Yield
  • EEX 1.23%
  • DVAX N/A
  • EPS Growth
  • EEX N/A
  • DVAX N/A
  • EPS
  • EEX 0.04
  • DVAX N/A
  • Revenue
  • EEX $432,600,000.00
  • DVAX $316,268,000.00
  • Revenue This Year
  • EEX $17.23
  • DVAX $23.23
  • Revenue Next Year
  • EEX $6.65
  • DVAX $16.57
  • P/E Ratio
  • EEX $132.44
  • DVAX N/A
  • Revenue Growth
  • EEX 9.96
  • DVAX 26.66
  • 52 Week Low
  • EEX $3.22
  • DVAX $9.20
  • 52 Week High
  • EEX $5.45
  • DVAX $14.63
  • Technical
  • Relative Strength Index (RSI)
  • EEX 44.27
  • DVAX 52.11
  • Support Level
  • EEX $4.85
  • DVAX $9.95
  • Resistance Level
  • EEX $5.04
  • DVAX $10.35
  • Average True Range (ATR)
  • EEX 0.19
  • DVAX 0.29
  • MACD
  • EEX -0.03
  • DVAX 0.08
  • Stochastic Oscillator
  • EEX 27.08
  • DVAX 75.00

About EEX Emerald Holding Inc.

Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: